In the last trading session, 1.17 million Tempest Therapeutics Inc (NASDAQ:TPST) shares changed hands as the company’s beta touched -1.84. With the company’s per share price at $0.81 changed hands at -$0.06 or -7.36% during last session, the market valuation stood at $35.20M. TPST’s last price was a discount, traded about -640.74% off its 52-week high of $6.00. The share price had its 52-week low at $0.70, which suggests the last value was 13.58% up since then.
Analysts gave the Tempest Therapeutics Inc (TPST) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TPST as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Tempest Therapeutics Inc’s EPS for the current quarter is expected to be -0.25.
Tempest Therapeutics Inc (NASDAQ:TPST) trade information
Instantly TPST was in red as seen at the end of in last trading. With action -12.73%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -3.33%, with the 5-day performance at -12.73% in the red. However, in the 30-day time frame, Tempest Therapeutics Inc (NASDAQ:TPST) is -15.09% down.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 62.66%. The 2025 estimates are for Tempest Therapeutics Inc earnings to increase by 29.54%, but the outlook for the next 5-year period is at 12.39% per year.
TPST Dividends
Tempest Therapeutics Inc is expected to release its next quarterly earnings report in March.
FMR LLC holds the second largest percentage of outstanding shares, with 1.9426% or 0.43 million shares worth $0.95 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . With 226.2 shares estimated at $0.18 million under it, the former controlled 0.52% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.40% of the shares, roughly 174.01 shares worth around $0.14 million.
